Bioelectronics Corp (BIEL)

[seven-up]

THERE-ARE-SEVERAL-REASONS-TO-INVEST-IN-BIEL-TODAY

1. FDA full body approval of Actipatch for muscle and joint.....waiting for the approval as we speak

2. Bayer. Dr Scholl’s licensing agreement......waiting for the deal as we speak

3. RecoveryRx approval and entry in the FDA innovation challenge.....We should hear something in November

4. Allay for menstrual pain. Clinical trial followed by 510 application is expected later this year. A new clinical trial for Allay is expected to be completed in October, by a prestigious institution in the UK with NHS foundation funding.

5. Actipatch for migraines.....currently under review after the completion of the clinical trial

6. Major US retailer.....Stay Tuned

7. More Licensing.....Stay Tuned